Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia

Journal of Opioid Management

Volumn 10, Issue 6, 2014, Pages 383-393

  Chen, Lucy ^a   Sein, Michael ^a   Vo, Trang ^a   Amhmed, Shihab ^a   Zhang, Yi ^a   St Hilaire, Kristin ^a   Houghton, Mary ^a   Mao, Jianren ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Opioid; Opioid tolerance; Opioid induced hyperalgesia; Pain; Primary care

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; E-MAIL; HEALTH SURVEY; HUMAN; HYPERALGESIA; MEDICAL PRACTICE; OPIOID INDUCED HYPERALGESIA; PHYSICIAN; ATTITUDE TO HEALTH; CHEMICALLY INDUCED; CLINICAL COMPETENCE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG TOLERANCE; HEALTH CARE SURVEY; NOCICEPTION; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PREDICTIVE VALUE; PSYCHOLOGY; QUESTIONNAIRE; TIME; UNITED STATES;

ANALGESICS, OPIOID; CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERALGESIA; PAIN; PAIN MEASUREMENT; PAIN PERCEPTION; PAIN THRESHOLD; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; TIME FACTORS; UNITED STATES;

EID: 84924354106     PISSN: 15517489     EISSN: 23750146     Source Type: Journal    
DOI: 10.5055/jom.2014.0235     Document Type: Article

References (79)

1. Ballantyne JC, Mao J: Opioid therapy for chronic pain. NEngl J Med. 2003; 349(20): 1943-1953.
2. Ballantyne JC: Opioid analgesia: Perspectives on right use and utility. Pain Physician. 2007; 10(3): 479-491.
3. Angst MS, Phillips NG, Drover DR, et al.: Pain sensitivity and opioid analgesia: A pharmacogenomic twin study. Pain. 2012; 153(7): 1397-1409.
4. He L, Kim JA, Whistler JL: Biomarkers of morphine tolerance and dependence are prevented by morphine-induced endocy-tosis of a mutant mu-opioid receptor. FASEB J. 2009; 23(12): 4327-4334.
5. Ravindranathan A, Joslyn G, Robertson M, et al.: Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA. 2009; 106(26): 10811-10816.
6. Lee M, Silverman SM, Hansen H, et al.: A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2): 145-161.
7. Low Y, Clarke CF, Huh BK: Opioid-induced hyperalgesia: A review of epidemiology, mechanisms and management. Singapore Med J. 2012; 53(5): 357-360.
8. Bianchi E, Norcini M, Smrcka A, et al.: Supraspinal gbet-agamma-dependent stimulation of PLCbeta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia. JNeurochem. 2009; 111(1): 171-180.
9. Bianchi E, Galeotti N, Menicacci C, et al.: Contribution of G inhibitory protein alpha subunits in paradoxical hyperalgesia elicited by exceedingly low doses of morphine in mice. Life Sci. 2011; 89(25-26): 918-925.
10. Celerier E, Gonzalez JR, Maldonado R, et al.: Opioid-induced hyperalgesia in a murine model of postoperative pain: Role of nitric oxide generated from the inducible nitric oxide synthase. Anesthesiology. 2006; 104(3): 546-555.
11. Chen Y, Yang C, Wang ZJ: Ca2+Vcalmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia. J Neumsci. 2010; 30(1): 38-46.
12. Cui W, Li Y, Li S, et al.: Systemic lidocaine inhibits remifenta-nil-induced hyperalgesia via the inhibition of cPKCgamma membrane translocation in spinal dorsal horn of rats./Neurosurg Anesthesiol. 2009; 21(4): 318-325.
13. Esmaeili-Mahani S, Shimokawa N, Javan M, et al.: Low-dose morphine induces hyperalgesia through activation of G alphas, protein kinase C, and L-type Ca2+ channels in rats./Neurosci Res. 2008; 86(2): 471-479.
14. Ghelardini C, Galeotti N, Vivoli E, et al.: Molecular interaction in the mouse PAG between NMDA and opioid receptors in morphine-induced acute thermal nociception./Nenrochem. 2008; 105(1): 91-100.
15. Gu X, Wu X, Liu Y, et al.: Tyrosine phosphorylation of the N-methyl-n-aspartate receptor 2B subunit in spinal cord contributes to remifentanil-induced postoperative hyperalgesia: The preventive effect of ketamine. MolPain. 2009; 5: 76.
16. Gupta LK, Gupta R, Tripathi CD: N-methyl-n-aspartate receptor modulators block hyperalgesia induced by acute low-dose morphine. Clin Exp Pharmacol Physiol. 2011; 38(9): 592-597.
17. Liang DY, Li X, Clark JD: 5-Hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology. 2011; 114(5): 1180-1189.
18. Mao J, Sung B, Ji RR, et al.: Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22(18): 8312-8323.
19. Mao J, Sung B, Ji RR, et al.: Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002; 22(17): 7650-7661.
20. Mao J: Opioid-induced abnormal pain sensitivity. CutrPain Headache Rep. 2006; 10(1): 67-70.
21. Minville V, Fourcade O, Girolami JP, et al.: Opioid-induced hyperalgesia in a mice model of orthopaedic pain: Preventive effect of ketamine. Br JAnaesth. 2010; 104(2): 231-238.
22. Rivat C, Vera-Portocarrero LP, Ibrahim MM, et al.: Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain. Eur J Neurosci. 2009; 29(4): 727-737.
23. Ruiz-Medina J, Ledent C, Valverde O: GPR3 orphan receptor is involved in neuropathic pain after peripheral nerve injury and regulates morphine-induced antinociception. Neuropharmacology. 2011; 61(1-2): 43-50.
24. Simonin F, Schmitt M, Laulin JP, et al.: RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA. 2006; 103(2): 466-471.
25. Van ELstraete AC, Sitbon P, Mazoit JX, et al.: Protective effect of prior administration of magnesium on delayed hyperalgesia induced by fentanyl in rats. Can JAnaesth. 2006; 53(12): 1180-1185.
26. Vanderah TW, Ossipov MH, Lai J, et al.: Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin. Pain. 2001; 92(1-2): 5-9.
27. Vardanyan A, Wang R, Vanderah TW, et al.: TRPV1 receptor in expression of opioid-induced hyperalgesia. J Pain. 2009; 10(3): 243-252.
28. Vera-Portocarrero LP, Zhang ET, King T, et al.: Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain. 2007; 129(1-2): 35-45.
29. Zhao M, Joo DT: Enhancement of spinal N-methyl-D-aspartate receptor function by remifentanil action at delta-opioid receptors as a mechanism for acute opioid-induced hyperalgesia or tolerance. Anesthesiology. 2008; 109(2): 308-317.
30. Zhou HY, Chen SR, Chen H, et al.: Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J Neurosci. 2010; 30(12): 4460-4466.
31. Wei X, Wei W: Role of gabapentin in preventing fenta-nyl-and morphine-withdrawal-induced hyperalgesia in rats. J Anesth. 2012; 26(2): 236-241.
32. Liang DY, Liao G, Lighthall GK, et al.: Genetic variants of the P-glycoprotein gene Abcblb modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics. 2006; 16(11): 825-835.
33. Liang DY, Liao G, Wang J, et al.: A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006; 104(5): 1054-1062.
34. Wilson NM, Jung H, Ripsch MS, et al.: CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immiin. 2011; 25(3): 565-573.
35. Mao J: Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain. 2002; 100(3): 213-217.
36. Chang G, Chen L, Mao J: Opioid tolerance and hyperalgesia. Med Clin North Am. 2007; 9K2: 199-211.
37. Chou R: 2009 clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: What are the key messages for clinical practice? Pol Arch Med Wewn. 2009; 119(7-8): 469-477.
38. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
39. Chapman CR, Lipschitz DL, Angst MS, et al.: Opioid pharmacotherapy for chronic non-cancer pain in the united states: A research guideline for developing an evidence-base. J Pain. 2010; 11(9): 807-829.
40. Chen L, Vo T, Seefeld L, et al.: Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients. J Pain. 2013; 14(4): 384-392.
41. Upshur CC, Luckmann RS, Savageau JA: Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006; 21(6): 652-655.
42. Upshur CC, Bacigalupe G, Luckmann R: "They don't want anything to do with you": Patient views of primary care management of chronic pain. Pain Med. 2010; 11(12): 1791-1798.
43. Bhamb B, Brown D, Hariharan J, et al.: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. CurrMedRes Opin. 2006; 22(9): 1859-1865.
44. Mahowald ML, Singh JA, Majeski P: Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum. 2005; 52(1): 312-321.
45. Chen L, Malarick C, Seefeld L, et al.: Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain. 2009; 143(1-2): 65-70.
46. Anand KJ, Willson DF, Berger J, et al.: Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics. 2010; 125(5): el208-el225.
47. Arnold JH, Truog RD, Orav EJ, et al.: Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology. 1990; 73(6): 1136-1140.
48. Arnold JH, Truog RD, Scavone JM, et al.: Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. J Pediatr. 1991; 119(4): 639-643.
49. Ceger P, Kuhn CM: Opiate withdrawal in the neonatal rat: Relationship to duration of treatment and naloxone dose. Psychophartnacology (Bed). 2000; 150(3): 253-259.
50. Buntin-Mushock C, Phillip L, Moriyama K, et al.: Age-dependent opioid escalation in chronic pain patients. Anesth Analg. 2005; 100(6): 1740-1745.
51. Sagheer MA, Khan MF, Sharif S: Association between chronic low back pain, anxiety and depression in patients at a tertiary care centre. J Pak Med Assoc. 2013; 63(6): 688-690.
52. Kroenke K, Outcalt S, Krebs E, et al.: Association between anxiety, health-related quality of life and functional impairment in primary care patients with chronic pain. Gen Hosp Psychiatry. 2013; 35(4): 359-365.
53. 53-Kim H, Chen L, Lim G, et al.: Brain indoleamine 2,3-dioxy-genase contributes to the comorbidity of pain and depression. J Clin Invest. 2012; 122(8): 2940-2954.
54. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation: Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage. 2009; 38(3): 418-425.
55. Davis MP: Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012; 10(6): 209-219.
56. Chindalore VL, Craven RA, Yu KP, et al.: Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A randomized, controlled trial of oxytrex. J Pain. 2005; 6(6): 392-399
57. Webster LR: Oxytrex: An oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007; 16(8): 1277-1283.
58. Webster LR, Fine PG: Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012; 13(4): 562-570.
59. Von Korff M, Kolodny A, Deyo RA, et al.: Long-term opioid therapy reconsidered. Ann Intern Med. 2011; 155(5): 325-328.
60. Khan MI, Walsh D, Brito-Dellan N: Opioid and adjuvant analgesics: Compared and contrasted. Am JHosp PalliatCare. 2011; 28(5): 378-383
61. Kapural L, Kapural M, Bensitel T, et al.: Opioid-sparing effect of intravenous outpatient ketamine infusions appears short-lived in chronic-pain patients with high opioid requirements. Pain Physician. 2010; 13(4): 389-394.
62. Prommer EE: Ketamine for pain: An update of uses in palliative care./Palliat Med. 2012; 15(4): 474-483.
63. Raffa RB, Pergolizzi JV Jr: Opioid-induced hyperalgesia: Is it clinically relevant for the treatment of pain patients? Pain ManagNurs. 2013; 14(3): e67-e83.
64. Ma JF, Huang ZL, Li J, et al.: Cohort study of remifentanil-induced hyperalgesia in postoperative patients. Zhonghua Yi XueZaZhi. 2011; 91(14): 977-979.
65. Pohl M, Smith L: Chronic pain and addiction: Challenging co-occurring disorders. J Psychoactive Drugs. 2012; 44(2): 119-124.
66. Modesto-Lowe V, Girard L, Chaplin M: Cancer pain in the opioid-addicted patient: Can we treat it right? J Opioid Manag. 2012; 8(3): 167-175.
67. Pud D, Cohen D, Lawental E, et al.: Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend. 2006; 82(3): 218-223.
68. Fishbain DA, Lewis JE, Gao J: Are psychoactive substance (opioid)-dependent chronic pain patients hyperalgesic? Pain Pract. 2011; 11(4): 337-343.
69. Suzan E, Eisenberg E, Treister R, et al.: A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: Is hydromorphone therapy a double-edged sword? Pain Physician. 2013; 16(1): 65-76.
70. HayJL, White JM, Bochner F, et al.: Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain. 2009; 10(3): 316-322.
71. Compton P, Charuvastra VC, Ling W: Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend. 2001; 63(2): 139-146.
72. Vinik HR, Kissin I: Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg. 1998; 86(6): 1307-1311.
73. 73-Mao J, Price DD, Mayer DJ: Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain. 1995; 62(3): 259-274.
74. Devulder J: Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain./Neurosurg Anesthesiol. 1997; 9(2): 146-148.
75. Sjogren P, Jensen NH, Jensen TS: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994; 59(2): 313-316.
76. Vorobeychik Y, Chen L, Bush MC, et al.: Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008; 9(6): 724-727.
77. Wilson GR, Reisfield GM: Morphine hyperalgesia: A case report. AmJHosp Palliat Care. 2003; 20(6): 459-461.
78. Atluri S, Akbik H, Sudarshan G: Prevention of opioid abuse in chronic non-cancer pain: An algorithmic, evidence based approach. Pain Physician. 2012; 15(3 Suppl): ES177-ES189.
79. 79-Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-Evidence assessment. Pain Physician. 2012; 15(3 Suppl): S1-S65.